Circulating Tumor Cells Predict Relapse in Stage III Melanoma
FRIDAY, Feb. 7, 2020 -- For stage III melanoma patients, circulating tumor cells (CTCs) predict relapse, according to a study published online Feb. 3 in Clinical Cancer Research.
Anthony Lucci, M.D., from the University of Texas MD Anderson Cancer...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Melanoma | Pharmaceuticals | Skin Cancer | Study | Texas University